![]() |
Volumn 15, Issue 6, 2004, Pages 575-579
|
Dose-ranging trial with a recombinant urokinase (urokinase alfa) for occluded central venous catheters in oncology patients
g
NONE
(United States)
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ALTEPLASE;
CATHFLO ACTIVASE;
PLACEBO;
PLASMINOGEN ACTIVATOR;
RECOMBINANT UROKINASE;
UNCLASSIFIED DRUG;
UROKINASE;
UROKINASE ALPHA;
ADOLESCENT;
ADULT;
ALLERGY;
ANTICOAGULATION;
ARTICLE;
BLEEDING;
CANCER PATIENT;
CENTRAL VENOUS CATHETER;
CENTRAL VENOUS CATHETERIZATION;
CHILD;
CLINICAL TRIAL;
CONCENTRATION RESPONSE;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DOSE CALCULATION;
DOSE TIME EFFECT RELATION;
DOUBLE BLIND PROCEDURE;
DRUG EFFICACY;
DRUG SAFETY;
EPISTAXIS;
EVALUATION;
FEMALE;
HEMATURIA;
HUMAN;
INJECTION SITE;
MAJOR CLINICAL STUDY;
MALE;
METRORRHAGIA;
MOLECULAR WEIGHT;
MULTIPLE ORGAN FAILURE;
PARALLEL DESIGN;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
STATISTICAL ANALYSIS;
STATISTICAL SIGNIFICANCE;
SUBARACHNOID HEMORRHAGE;
THROMBOCYTOPENIA;
VASCULAR ACCESS;
VEIN OCCLUSION;
|
EID: 2942556571
PISSN: 10510443
EISSN: None
Source Type: Journal
DOI: 10.1097/01.RVI.0000124950.24134.19 Document Type: Article |
Times cited : (13)
|
References (8)
|